• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    From Lab Rats And Eyeballs To Cannabis: Scarlet Express CEO Discusses Closed-Loop Delivery, How To 'Survive In Chaos'

    7/4/24 9:43:18 AM ET
    $CAH
    $MCK
    Other Pharmaceuticals
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email

    First, Claudia Post oversaw the safe delivery of eyeballs, kidneys and other organs. Today? Her specialty is cannabis.

    Most recently, she launched Scarlet Express with financial backing from Ben Sopranzetti, vice chair of the Department of Finance and Economics at Rutgers Business School.

    The Philadelphia-based startup is a state-approved, closed-loop delivery organization providing discreet, secure and expert cannabis supply chain management nationwide.

    And Post is the perfect person for this type of venture. A serial entrepreneur, Post launched MOST Consulting Group, a one-stop shop for cannabis marketing and advertising, and founded Diamond Transportation Group, a same-day, time-critical delivery service, in the early 1990s.

    See Also: $2.9B European Cannabis Market: A Strategic Blueprint For Cross-Border Transportation Logistics

    Post went on to open 12 warehouses along the East Coast offering trucking, pick-pack-ship, logistics and other services. And anyone who follows the inner workings of the nascent cannabis industry knows that transporting marijuana across state lines is fraught with challenges.

    Despite President Joe Biden’s proposal to reclassify marijuana from its position as a Schedule I drug to a less dangerous Schedule III, a mishmash of federal and state laws, combined with varying enforcement policies, makes interstate transport federally illegal and a headache for businesses.

    Benzinga spoke with Post at the recent Benzinga Cannabis Market Spotlight event. Here’s what she had to say about the dire need for efficient cannabis transportation:

    BZ: How did you wind up in cannabis?

    Post: I’ve been in the cannabis industry for 14 years. I opened a marketing communications agency called MOST Consulting. We do design, content, strategy — anything in the communication space. Need a truck wrap? We’ll do a truck wrap.

    Also, my son is a very famous glassblower. He makes pipes, bongs and collectibles. His nom de plume is Snick Barnes. He’s in Philly, but he’s known all over the world. And he said, “Ma, you’ve got to get into cannabis. It’s going to blow up.” I said, “Okay.” And he was absolutely right.

    BZ: He was ahead of the curve.

    I’d like to think our little family is. Then I started going to things like Champs Trade Shows. And when medical cannabis started emerging, I worked with the then-governor of Pennsylvania to bring medical marijuana to the state.

    But before that, I had a rather large, multi-state transportation company called Diamond. I had 12 locations up and down the East Coast.

    BZ: What were you transporting?

    We did same-date, time-critical delivery. Some of my clients were large pharmaceutical distributors like Cardinal Health (NYSE:CAH) and McKesson Corp (NYSE:MCK). So, I understand the compliance and the necessity for handling schedule one narcotics, etcetera. We would also move lab rats that were [valued at] $20,000. We would do all kinds of deliveries like body parts, eyeballs, kidneys…

    BZ: Organ transplants?

    Yes.

    BZ: How much ice do you need to transport organs? A lot, right?

    Yes. And it’s a very specialized pickup and delivery. Let’s say the eyeballs were in California. We would get an alert and have our affiliate in Los Angeles pick up the part, and put it on the plane.

    All of my drivers were TSA-certified, which means they’re excruciatingly detailed. We put freight in the belly of the plane. And that was tracked through to the operatory and done correctly within the compliance of the TSA.

    So, the magnitude of my understanding of being compliant is very high. I would hazard to say, I don’t know anybody in the cannabis industry who has the background that I do — in transportation, anyway.

    BZ: Are your hopes high for later this year that cannabis will be rescheduled?

    I don’t think it’ll happen this year. But I have hopes. Hope isn’t always a strategy, but I do have hopes that it will happen. And we should have de-scheduling, not rescheduling. De-scheduling means it’s just like we could go buy beer. Rescheduling means it goes into another category that is monitored, tracked, and all that other s—. Sorry, I’m very direct.

    BZ: What is the focus of Scarlet Express?

    We pick it up at a “grow;” take it to a dispensary; pick it up at the manufacturer; pick it up at a dispensary and take it to you. I’m a startup, and I have letters of intent. The difference between me and others is many years of experience and understanding of what you need to be compliant and mitigate risk.

    BZ: What sort of challenges do you foresee in cannabis transportation?

    You have a bunch of legislators writing policy, and not understanding anything about delivery. That is what often happens.

    Why do things in isolation, when you have a world of people you could call on? Pennsylvania held a symposium where they called in a variety of people to testify, including someone from Massachusetts, which has one of the most onerous [cannabis transportation] policies. Ask experts. Ask somebody who knows what delivery is about.

    BZ: How did New Jersey roll out its cannabis program?

    It had its problems, just like every other state. It was slow. I testified before the Cannabis Regulatory Commission (CRC). This lovely man rented a space, paying something like $18,000 a month, and the CRC is sitting on it for two years. They haven’t actualized his license. Why? My heart bleeds. I ache for people who are being taken advantage of. It’s just terrible.

    BZ: What do you want potential clients/investors to know about Scarlet Express?

    If someone were to come to me and say, “I’ve got $75 million, and I want to have the largest national delivery service,” I would say, because of my background and years of experience in transportation, “I’m a sure bet.” I already built a large company in transportation. My network is very deep across the country. I also understand high-value, compliant delivery, as well as the insurance component and how to scale anywhere.

    I’m a problem solver. The basic thing about somebody in logistics, is you have to be able to survive in chaos. And you have to be able to make decisions quickly, turn on a dime. If there’s ever an issue with a driver, we have to send somebody to relay [cargo] wherever it has to go. You have to be able to think quickly.

    BZ: With your expertise, you could handle logistics for anything. Why cannabis?

    People always ask me, “How do I get in the industry?” Take a skill set. I know delivery and transportation inside and out. And it just seems natural to me because I own the marketing agency and they sort of dovetail together.

    Now Read:

    • Can Cannabis ‘Bring Retail Back To Life'? Verano, Curaleaf, NewLake Capital Bet Big On Local New Jersey Market

    Photo: Benzinga

    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH
    $MCK

    CompanyDatePrice TargetRatingAnalyst
    Cardinal Health Inc.
    $CAH
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    Cardinal Health Inc.
    $CAH
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    Cardinal Health Inc.
    $CAH
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    Cardinal Health Inc.
    $CAH
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    Cardinal Health Inc.
    $CAH
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    Cardinal Health Inc.
    $CAH
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    McKesson Corporation
    $MCK
    12/4/2024$630.00Neutral
    Mizuho
    Cardinal Health Inc.
    $CAH
    12/4/2024$139.00Outperform
    Mizuho
    More analyst ratings

    $CAH
    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Unveils State-of-the-Art Consumer Health Logistics Center

    DUBLIN, Ohio, Sept. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today is showcasing its newly operational Consumer Health Logistics Center, a 350,000-square-foot facility in Groveport, Ohio. Purpose-built as a centralized replenishment hub, this facility serves as a vital link in the company's supply chain, efficiently distributing over-the-counter medications, treatments, and diagnostic solutions to a network of more than 20 forward distribution centers serving customers nationwide.  "This first-of-its kind hub marks another key milestone in our multi-year strategy to

    9/15/25 12:00:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $MCK
    SEC Filings

    View All

    $CAH
    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CAH
    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/27/25 5:02:44 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 8-K filed by Cardinal Health Inc.

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by Cardinal Health Inc.

    FWP - CARDINAL HEALTH INC (0000721371) (Subject)

    8/13/25 4:44:29 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Tyler Brian S. sold $8,418,166 worth of shares (11,930 units at $705.63), decreasing direct ownership by 75% to 4,012 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/25/25 4:30:05 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    CEO, PSS Segment Weitzman Deborah sold $3,216,375 worth of shares (21,367 units at $150.53), decreasing direct ownership by 29% to 53,428 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/20/25 4:12:43 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Hollar Jason M. sold $5,386,566 worth of shares (35,901 units at $150.04), decreasing direct ownership by 15% to 200,000 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/20/25 4:12:08 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Jefferies with a new price target

    Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

    2/5/25 7:09:45 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by TD Cowen with a new price target

    TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

    1/8/25 7:36:58 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $MCK
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv

    8/6/25 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $CAH
    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care